Literature DB >> 21620790

TLRs innate immunereceptors and Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) CIDR1α-driven human polyclonal B-cell activation.

Olivia Simone1, Maria Teresa Bejarano, Susan K Pierce, Salvatore Antonaci, Mats Wahlgren, Marita Troye-Blomberg, Daria Donati.   

Abstract

Chronic malaria severely affects the immune system and causes polyclonal B-cell activation, as evidenced by the presence of hypergammaglobulinemia, elevated levels of autoantibodies, loss of B-cell memory and the frequent occurrence of Burkitt's lymphomas (BL) in children living in malaria endemic areas. Previous studies have shown that the cysteine-rich interdomain region 1α (CIDR1α) of the Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) of the FCR3S1.2 strain, subsequently named CIDR1α, interacts with B cells partially through the binding to the B-cell receptor (BCR). This interaction leads to an activated phenotype, increased survival, and a low degree of proliferation. CIDR1α preferentially activates the memory B-cell compartment, therefore PfEMP1 is considered to act as a polyclonal B-cell activator and its role in memory maintenance has been suggested. In this report, we extend the analysis of the PfEMP1-CIDR1α B-cell interaction and demonstrate that PfEMP1-CIDR1α increases the expression of TLR7 and TLR10 mRNA transcripts and sensitizes B cells to TLR9 signalling via the MyD88 adaptor molecule. Furthermore, despite its ability to bind to surface Igs, PfEMP1-CIDR1α-induced B-cell activation does not seem to proceed through the BCR, since it does not induce Lyn and/or phospho-tyrosine mediated signalling pathways. Rather PfEMP1-CIDR1α induces the phosphorylation of downstream kinases, such as ERK1/2, p38 and IKBα, in human B cells. These findings indicate that PfEMP1-CIDR1α induces a persistent activation of B cells, which in turn can contribute to the exhaustion and impairment of B-cell functions during chronic malaria infection.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21620790      PMCID: PMC3406598          DOI: 10.1016/j.actatropica.2011.05.005

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  39 in total

Review 1.  Dendritic cells in a mature age.

Authors:  Caetano Reis e Sousa
Journal:  Nat Rev Immunol       Date:  2006-06       Impact factor: 53.106

Review 2.  Toll-like receptors and innate immunity in B-cell activation and antibody responses.

Authors:  Antonio Lanzavecchia; Federica Sallusto
Journal:  Curr Opin Immunol       Date:  2007-04-12       Impact factor: 7.486

Review 3.  Cooperation of Toll-like receptor signals in innate immune defence.

Authors:  Giorgio Trinchieri; Alan Sher
Journal:  Nat Rev Immunol       Date:  2007-03       Impact factor: 53.106

4.  Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication.

Authors:  Prapaporn Pisitkun; Jonathan A Deane; Michael J Difilippantonio; Tatyana Tarasenko; Anne B Satterthwaite; Silvia Bolland
Journal:  Science       Date:  2006-05-18       Impact factor: 47.728

5.  Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors.

Authors:  Elizabeth A Leadbetter; Ian R Rifkin; Andreas M Hohlbaum; Britte C Beaudette; Mark J Shlomchik; Ann Marshak-Rothstein
Journal:  Nature       Date:  2002-04-11       Impact factor: 49.962

6.  Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.

Authors:  Veit Hornung; Simon Rothenfusser; Stefanie Britsch; Anne Krug; Bernd Jahrsdörfer; Thomas Giese; Stefan Endres; Gunther Hartmann
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

7.  Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation.

Authors:  Jonathan A Deane; Prapaporn Pisitkun; Rebecca S Barrett; Lionel Feigenbaum; Terrence Town; Jerrold M Ward; Richard A Flavell; Silvia Bolland
Journal:  Immunity       Date:  2007-11-08       Impact factor: 31.745

8.  Superantigen- and TLR-dependent activation of tonsillar B cells after receptor-mediated endocytosis.

Authors:  Johan Jendholm; Matthias Mörgelin; Maria Laura A Perez Vidakovics; Michael Carlsson; Hakon Leffler; Lars-Olaf Cardell; Kristian Riesbeck
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

9.  The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens.

Authors:  Akanksha Chaturvedi; David Dorward; Susan K Pierce
Journal:  Immunity       Date:  2008-05-29       Impact factor: 31.745

10.  How location governs toll-like receptor signaling.

Authors:  Akanksha Chaturvedi; Susan K Pierce
Journal:  Traffic       Date:  2009-06       Impact factor: 6.215

View more
  22 in total

Review 1.  Pathogen manipulation of B cells: the best defence is a good offence.

Authors:  Katharina Nothelfer; Philippe J Sansonetti; Armelle Phalipon
Journal:  Nat Rev Microbiol       Date:  2015-02-09       Impact factor: 60.633

2.  Expanding the toolbox in pursuit of a strain transcendent malaria vaccine.

Authors:  Anne E P Frosch; Chandy C John
Journal:  Am J Trop Med Hyg       Date:  2014-11-24       Impact factor: 2.345

3.  Epstein-Barr Virus Genomes Reveal Population Structure and Type 1 Association with Endemic Burkitt Lymphoma.

Authors:  Jeffrey A Bailey; Ann M Moormann; Yasin Kaymaz; Cliff I Oduor; Ozkan Aydemir; Micah A Luftig; Juliana A Otieno; John Michael Ong'echa
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

4.  Burkitt lymphoma expresses oncofetal chondroitin sulfate without being a reservoir for placental malaria sequestration.

Authors:  Mette Ø Agerbaek; Marina A Pereira; Thomas M Clausen; Caroline Pehrson; Htoo Zarni Oo; Charlotte Spliid; Jamie R Rich; Vincent Fung; Francis Nkrumah; Janet Neequaye; Robert J Biggar; Steven J Reynolds; Giovanna Tosato; Sheeja T Pullarkat; Leona W Ayers; Thor G Theander; Mads Daugaard; Kishor Bhatia; Morten A Nielsen; Sam M Mbulaiteye; Ali Salanti
Journal:  Int J Cancer       Date:  2017-02-06       Impact factor: 7.396

Review 5.  Epstein-Barr virus: Biology and clinical disease.

Authors:  Blossom Damania; Shannon C Kenney; Nancy Raab-Traub
Journal:  Cell       Date:  2022-09-15       Impact factor: 66.850

6.  Blood-stage malaria of Plasmodium chabaudi induces differential Tlr expression in the liver of susceptible and vaccination-protected Balb/c mice.

Authors:  Saleh Al-Quraishy; Mohamed A Dkhil; Suliman Alomar; Abdel Azeem S Abdel-Baki; Denis Delic; Frank Wunderlich; Marcos J Araúzo-Bravo
Journal:  Parasitol Res       Date:  2016-01-25       Impact factor: 2.289

Review 7.  Using two phases of the CD4 T cell response to blood-stage murine malaria to understand regulation of systemic immunity and placental pathology in Plasmodium falciparum infection.

Authors:  Komi Gbedande; Victor H Carpio; Robin Stephens
Journal:  Immunol Rev       Date:  2020-01       Impact factor: 12.988

8.  Dysfunctional adaptive immunity during parasitic infections.

Authors:  Ryan A Zander; Noah S Butler
Journal:  Curr Immunol Rev       Date:  2013-08-01

9.  BAFF and BAFF receptor levels correlate with B cell subset activation and redistribution in controlled human malaria infection.

Authors:  Anja Scholzen; Anne C Teirlinck; Else M Bijker; Meta Roestenberg; Cornelus C Hermsen; Stephen L Hoffman; Robert W Sauerwein
Journal:  J Immunol       Date:  2014-03-19       Impact factor: 5.422

10.  Relationship between Plasmodium falciparum malaria prevalence, genetic diversity and endemic Burkitt lymphoma in Malawi.

Authors:  W Thomas Johnston; Nora Mutalima; David Sun; Benjamin Emmanuel; Kishor Bhatia; Peter Aka; Xiaolin Wu; E Borgstein; G N Liomba; Steve Kamiza; Nyengo Mkandawire; Mkume Batumba; Lucy M Carpenter; Harold Jaffe; Elizabeth M Molyneux; James J Goedert; Daniel Soppet; Robert Newton; Sam M Mbulaiteye
Journal:  Sci Rep       Date:  2014-01-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.